Dermal macrophages acquire a TREM2-anchored profibrotic state in antiphospholipid syndrome that is reflected in the circulation
This study identifies that dermal macrophages in antiphospholipid syndrome adopt a TREM2-anchored, profibrotic state driven by lipid handling and stromal interactions, a tissue-specific program that is reflected in elevated circulating soluble TREM2 and osteopontin levels and correlates with renal dysfunction.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body is a vast network of blood vessels, the tiny pipes that deliver oxygen and nutrients to every corner of our tissues. Sometimes, the immune system, which is designed to protect us, mistakenly turns against these vessels. In a condition called antiphospholipid syndrome, the body produces antibodies that attack the proteins in our blood, leading to a state of chronic inflammation and a tendency for blood to clot. While doctors are good at treating the dangerous clots that form in large vessels, they have fewer tools for the smaller, more subtle damage that occurs in the tiny capillaries. This small-vessel disease can silently harm organs like the kidneys and skin, causing ulcers and scarring, yet the biological machinery driving this slow damage has remained largely a mystery.
To understand what is happening inside these damaged tissues, a team of researchers at the University of Michigan turned to the skin. Because the skin is accessible and shares many features with the blood vessels in our internal organs, it offers a clear window into the disease process. The scientists collected small skin samples from thirty patients with antiphospholipid syndrome and compared them with samples from fourteen healthy volunteers. Using a powerful technology that allows them to read the genetic instructions of individual cells, they mapped out the cellular landscape of the skin. They were not looking for a change in the number of cells, but rather for a change in the behavior of the cells that were already there.
The study revealed that the skin of patients with this syndrome had not changed in its basic makeup; the same types of cells were present in similar numbers as in healthy skin. However, the cells were acting very differently. The most significant changes were found in the immune cells known as macrophages, which act as the tissue's cleanup crew and repair team. In the patients, these macrophages had shifted into a specific, activated state. They began to express high levels of a protein called TREM2 and turned on a suite of genes related to handling fats and breaking down cellular debris. This state, which researchers call a lipid-associated program, suggests the cells are reacting to an environment rich in damaged fats and cellular waste, a common sign of chronic tissue injury.
These activated macrophages were not just sitting idle; they were actively communicating with their neighbors. The researchers found that these cells were producing large amounts of a protein called osteopontin, which is known to promote scarring and fibrosis. They were sending this signal to the structural cells of the skin, such as fibroblasts, which build the tissue framework. In response, the structural cells were sending signals back, including a protein called apolipoprotein E, which the macrophages were programmed to receive. This intense back-and-forth conversation between the immune cells and the structural cells creates a cycle that likely drives the thickening and scarring of the blood vessels, a hallmark of the disease.
Remarkably, the researchers discovered that this specific cellular activity in the skin was not hidden away. They found that the same proteins produced by these skin cells could be measured in the blood. Patients with higher levels of these proteins in their circulation also had the strongest signs of this activated macrophage state in their skin. Furthermore, the levels of these proteins in the blood told a story about the patients' kidney health. Those with higher levels of these markers tended to have lower kidney function, and patients who already had kidney disease showed the highest levels of one of these proteins, soluble TREM2. This suggests that the damage happening in the skin is a reflection of a broader problem affecting the body's small blood vessels, including those in the kidneys.
The findings offer a new way to look at antiphospholipid syndrome, moving beyond the focus on blood clots to the slow, scarring damage that occurs in the smallest vessels. By identifying a specific state of immune cells that drives this scarring, the study points to a potential target for future treatments. If doctors can learn to interrupt the conversation between these activated macrophages and the tissue cells, they might be able to stop or slow the progression of organ damage. While the study was limited to a single point in time and focused on the skin, the clear link between the tissue changes and the blood markers provides a promising path forward. It suggests that by looking at the skin and the blood, we can gain a deeper understanding of how this disease harms the body and perhaps find new ways to protect it.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.